Skip to main content
Top
Published in: Medical Oncology 5/2021

01-05-2021 | Gastric Cancer | Original Paper

Disease spectrum of gastric cancer susceptibility genes

Authors: Sophia K. McKinley, Preeti Singh, Kanhua Yin, Jin Wang, Jingan Zhou, Yujia Bao, Menghua Wu, Kush Pathak, John T. Mullen, Danielle Braun, Kevin S. Hughes

Published in: Medical Oncology | Issue 5/2021

Login to get access

Abstract

Pathogenic variants in germline cancer susceptibility genes can increase the risk of a large number of diseases. Our study aims to assess the disease spectrum of gastric cancer susceptibility genes and to develop a comprehensive resource of gene–disease associations for clinicians. Twenty-seven potential germline gastric cancer susceptibility genes were identified from three review articles and from six commonly used genetic information resources. The diseases associated with each gene were evaluated via a semi-structured review of six genetic resources and an additional literature review using a natural language processing (NLP)-based procedure. Out of 27 candidate genes, 13 were identified as gastric cancer susceptibility genes (APC, ATM, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH-Biallelic, PALB2, SMAD4, and STK11). A total of 145 gene–disease associations (with 45 unique diseases) were found to be associated with these 13 genes. Other gastrointestinal cancers were prominent among identified associations, with 11 of 13 gastric cancer susceptibility genes also associated with colorectal cancer, eight genes associated with pancreatic cancer, and seven genes associated with small intestine cancer. Gastric cancer susceptibility genes are frequently associated with other diseases as well as gastric cancer, with potential implications for how carriers of these genes are screened and managed. Unfortunately, commonly used genetic resources provide heterogeneous information with regard to these genes and their associated diseases, highlighting the importance of developing guides for clinicians that integrate data across available resources and the medical literature.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
3.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.CrossRef
5.
go back to reference Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16(2):e60-70.CrossRef Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16(2):e60-70.CrossRef
6.
go back to reference van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361–74.CrossRef van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361–74.CrossRef
8.
go back to reference Li J, Woods SL, Healey S, Beesley J, Chen X, Lee JS, et al. Point mutations in exon 1B of APC reveal gastric adenocarcinoma and proximal polyposis of the stomach as a familial adenomatous polyposis variant. Am J Hum Genet. 2016;98(5):830–42.CrossRef Li J, Woods SL, Healey S, Beesley J, Chen X, Lee JS, et al. Point mutations in exon 1B of APC reveal gastric adenocarcinoma and proximal polyposis of the stomach as a familial adenomatous polyposis variant. Am J Hum Genet. 2016;98(5):830–42.CrossRef
9.
go back to reference Worthley DL, Phillips KD, Wayte N, Schrader KA, Healey S, Kaurah P, et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut. 2012;61(5):774–9.CrossRef Worthley DL, Phillips KD, Wayte N, Schrader KA, Healey S, Kaurah P, et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut. 2012;61(5):774–9.CrossRef
10.
go back to reference Tedaldi G, Pirini F, Tebaldi M, Zampiga V, Cangini I, Danesi R, et al. Multigene panel testing increases the number of loci associated with gastric cancer predisposition. Cancers (Basel). 2019;11(9):1340.CrossRef Tedaldi G, Pirini F, Tebaldi M, Zampiga V, Cangini I, Danesi R, et al. Multigene panel testing increases the number of loci associated with gastric cancer predisposition. Cancers (Basel). 2019;11(9):1340.CrossRef
11.
go back to reference Chun N, Ford JM. Genetic testing by cancer site: stomach. Cancer J. 2012;18(4):355–63.CrossRef Chun N, Ford JM. Genetic testing by cancer site: stomach. Cancer J. 2012;18(4):355–63.CrossRef
12.
go back to reference Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10.CrossRef Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10.CrossRef
13.
go back to reference Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2018;67(7):1306–16.CrossRef Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2018;67(7):1306–16.CrossRef
14.
go back to reference Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol. 2012;30(35):4409–15.CrossRef Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol. 2012;30(35):4409–15.CrossRef
15.
go back to reference Capelle LG, Van Grieken NCT, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology. 2010;138(2):487–92.CrossRef Capelle LG, Van Grieken NCT, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology. 2010;138(2):487–92.CrossRef
16.
go back to reference Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJP, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209–15.CrossRef Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJP, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209–15.CrossRef
17.
go back to reference Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119(6):1447–53.CrossRef Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119(6):1447–53.CrossRef
18.
go back to reference Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32.CrossRef Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32.CrossRef
21.
go back to reference Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen–the clinical genome resource. N Engl J Med. 2015;372(23):2235–42.CrossRef Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen–the clinical genome resource. N Engl J Med. 2015;372(23):2235–42.CrossRef
25.
go back to reference Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., eds. Gene-NCBI®. Seattle (WA): University of Washington, Seattle, 2010 Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., eds. Gene-NCBI®. Seattle (WA): University of Washington, Seattle, 2010
27.
go back to reference Sahasrabudhe R, Lott P, Bohorquez M, Toal T, Estrada AP, Suarez JJ, et al. Germline mutations in PALB2, BRCA1, and RAD51C, which regulate DNA recombination repair, in patients with gastric cancer. Gastroenterology. 2017;152(5):983-6.e6.CrossRef Sahasrabudhe R, Lott P, Bohorquez M, Toal T, Estrada AP, Suarez JJ, et al. Germline mutations in PALB2, BRCA1, and RAD51C, which regulate DNA recombination repair, in patients with gastric cancer. Gastroenterology. 2017;152(5):983-6.e6.CrossRef
28.
go back to reference Petrovchich I, Ford JM. Genetic predisposition to gastric cancer. Semin Oncol. 2016;43(5):554–9.CrossRef Petrovchich I, Ford JM. Genetic predisposition to gastric cancer. Semin Oncol. 2016;43(5):554–9.CrossRef
29.
go back to reference Slavin TP, Weitzel JN, Neuhausen SL, Schrader KA, Oliveira C, Karam R. Genetics of gastric cancer: what do we know about the genetic risks? Transl Gastroenterol Hepatol. 2019;4:55.CrossRef Slavin TP, Weitzel JN, Neuhausen SL, Schrader KA, Oliveira C, Karam R. Genetics of gastric cancer: what do we know about the genetic risks? Transl Gastroenterol Hepatol. 2019;4:55.CrossRef
30.
go back to reference Bao Y, Deng Z, Wang Y, Kim H, Armengol VD, Acevedo F, et al. Using machine learning and natural language processing to review and classify the medical literature on cancer susceptibility genes. JCO Clin Cancer Inform. 2019;3:1–9.CrossRef Bao Y, Deng Z, Wang Y, Kim H, Armengol VD, Acevedo F, et al. Using machine learning and natural language processing to review and classify the medical literature on cancer susceptibility genes. JCO Clin Cancer Inform. 2019;3:1–9.CrossRef
31.
go back to reference Deng Z, Yin K, Bao Y, Armengol VD, Wang C, Tiwari A, et al. Validation of a semi-automated natural language processing-based procedure for meta-analysis of cancer susceptibility gene penetrance. JCO Clin Cancer Inform. 2019;3:1–9.CrossRef Deng Z, Yin K, Bao Y, Armengol VD, Wang C, Tiwari A, et al. Validation of a semi-automated natural language processing-based procedure for meta-analysis of cancer susceptibility gene penetrance. JCO Clin Cancer Inform. 2019;3:1–9.CrossRef
34.
go back to reference Plichta JK, Griffin M, Thakuria J, Hughes KS. What’s new in genetic testing for cancer susceptibility? Oncology (Williston Park). 2016;30(9):787–99.PubMed Plichta JK, Griffin M, Thakuria J, Hughes KS. What’s new in genetic testing for cancer susceptibility? Oncology (Williston Park). 2016;30(9):787–99.PubMed
35.
go back to reference Hughes KS, Zhou J, Bao Y, Singh P, Wang J, Yin K. Natural language processing to facilitate breast cancer research and management. Breast J. 2020;26(1):92–9.CrossRef Hughes KS, Zhou J, Bao Y, Singh P, Wang J, Yin K. Natural language processing to facilitate breast cancer research and management. Breast J. 2020;26(1):92–9.CrossRef
36.
go back to reference Braun D, Yang J, Griffin M, Parmigiani G, Hughes KS. A clinical decision support tool to predict cancer risk for commonly tested cancer-related germline mutations. J Genet Couns. 2018;27(5):1187–99.CrossRef Braun D, Yang J, Griffin M, Parmigiani G, Hughes KS. A clinical decision support tool to predict cancer risk for commonly tested cancer-related germline mutations. J Genet Couns. 2018;27(5):1187–99.CrossRef
37.
go back to reference Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025–31.CrossRef Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025–31.CrossRef
38.
go back to reference Teodorczyk U, Cybulski C, Wokołorczyk D, Jakubowska A, Starzyńska T, Lawniczak M, et al. The risk of gastric cancer in carriers of CHEK2 mutations. Fam Cancer. 2013;12(3):473–8.CrossRef Teodorczyk U, Cybulski C, Wokołorczyk D, Jakubowska A, Starzyńska T, Lawniczak M, et al. The risk of gastric cancer in carriers of CHEK2 mutations. Fam Cancer. 2013;12(3):473–8.CrossRef
39.
go back to reference Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the copenhagen general population study. J Clin Oncol. 2016;34(11):1208–16.CrossRef Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the copenhagen general population study. J Clin Oncol. 2016;34(11):1208–16.CrossRef
40.
go back to reference Kaczmarek-Ryś M, Ziemnicka K, Hryhorowicz ST, Górczak K, Hoppe-Gołębiewska J, Skrzypczak-Zielińska M, et al. The c.470 T > C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population. Hered Cancer Clin Pract. 2015;13(1):8.CrossRef Kaczmarek-Ryś M, Ziemnicka K, Hryhorowicz ST, Górczak K, Hoppe-Gołębiewska J, Skrzypczak-Zielińska M, et al. The c.470 T > C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population. Hered Cancer Clin Pract. 2015;13(1):8.CrossRef
41.
go back to reference Siołek M, Cybulski C, Gąsior-Perczak D, Kowalik A, Kozak-Klonowska B, Kowalska A, et al. CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer. 2015;137(3):548–52.CrossRef Siołek M, Cybulski C, Gąsior-Perczak D, Kowalik A, Kozak-Klonowska B, Kowalska A, et al. CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer. 2015;137(3):548–52.CrossRef
Metadata
Title
Disease spectrum of gastric cancer susceptibility genes
Authors
Sophia K. McKinley
Preeti Singh
Kanhua Yin
Jin Wang
Jingan Zhou
Yujia Bao
Menghua Wu
Kush Pathak
John T. Mullen
Danielle Braun
Kevin S. Hughes
Publication date
01-05-2021
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2021
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-021-01495-w

Other articles of this Issue 5/2021

Medical Oncology 5/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.